Cardarine (GW-501516) Research Guide

Full name: GW-501516 (Cardarine, Endurobol)

A PPAR-delta agonist (not a SARM) popular for endurance and fat-loss claims. Importantly, its pharmaceutical development was halted after long-term high-dose animal studies showed cancer development. It is banned in sport and carries serious safety warnings.

How Cardarine (GW-501516) Works

Activates the PPAR-delta nuclear receptor, shifting cells toward burning fat for fuel and upregulating genes involved in fatty-acid oxidation and endurance metabolism.

Dosing Protocol

• Typical dose: Commonly cited 10-20 mg/day (research)
• Frequency: Once daily
• Duration: Commonly cited short cycles
• Route: Oral

Reported Benefits

• Increased endurance (research claims)
• Enhanced fat oxidation
• No hormonal suppression
• Improved lipid profile in some studies

Potential Side Effects

• Cancer risk shown in long-term high-dose animal studies
• Unknown long-term human safety
• Banned by WADA
• Potential liver stress

Research Citations

1. GW-501516 and fatty-acid oxidation (2008) - Increased endurance and fat metabolism in mice via PPAR-delta activation.
2. Carcinogenicity findings halting development (2009) - Long-term high-dose rodent studies showed tumor development across multiple organs, ending clinical development.

Related Weight Management Compounds

• AOD-9604 - Full Profile
• Semaglutide - Full Profile
• Tirzepatide - Full Profile
• Retatrutide - Full Profile
• Tesofensine - Full Profile
• CagriSema - Full Profile

View full Cardarine (GW-501516) profile with 3D molecule viewer →